Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma

Affiliations

• ¹ Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: jianqingmi@shsmu.edu.cn.
• ² The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
• ³ Peking University Third Hospital, Beijing, China.
• ⁴ First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, China.
• ⁵ Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.